Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.
Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.
PatentVest (MDBH) will present at Planet MicroCap Las Vegas on June 17 at 11:30 AM PT. The firm will cover intellectual property strategy, innovation intelligence, and AI-native IP services, including outcome-based patent prosecution and Examination-Upfront workflows aimed at stronger, more scalable patent portfolios.
PatentVest (NASDAQ:MDBH) released a new PatentVest Pulse report titled “The Muscle Problem: How Myostatin Could Expand the GLP-1 Opportunity.” The study analyzes 20 muscle-preservation programs aimed at improving body composition during GLP-1-based obesity treatment.
The report reviews myostatin inhibition, ActRII blockade, and GLP-1 combination strategies, plus related intellectual property, clinical pipelines, and major transactions such as Eli Lilly’s Versanis Bio deal and AstraZeneca’s SixPeaks Bio acquisition.
MDB Capital (NASDAQ: MDBH) will present at the Planet MicroCap Las Vegas 2026 conference, alongside subsidiary PatentVest and portfolio company Buda Juice (NYSE American: BUDA).
Executives will host live webcasts, Q&A sessions, and 1x1 investor meetings on June 17, 2026.
PatentVest (MDBH) launched a new Case Studies section on its website, debuting with a feature on AI company Docana. The case study details how PatentVest helped Docana analyze the AI patent landscape, define freedom-to-operate boundaries, and build a strategic framework for patent and trade secret protection.
PatentVest released a Pulse report (May 8, 2026) mapping the emerging triple-agonist obesity race and an intensifying patent battle shaping the post-GLP-1 market.
Key points: identification of 27 global triple-agonist programs, Eli Lilly’s retatrutide cited for near‑bariatric efficacy, rising importance of receptor‑ratio engineering, delivery platforms, formulation control, and latent IP holdings from multiple firms that could reshape future competition.
PatentVest released a April 29, 2026 report titled “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery.” Retatrutide achieved 28.7% mean weight loss, described as the first non-surgical therapy matching bariatric outcomes. The report maps the pipeline, deal activity, and IP structure, noting multiple industry entrants (Novo Nordisk, Pfizer via acquisition, Hanmi, Innovent, Hengrui) and that Sanofi holds the largest IP position with 27 programs. PatentVest warns the trial result may not hold in real-world use and highlights IP control and access as the next battleground.
MDB Capital Holdings (NASDAQ: MDBH) provided a 2025 full-year update and shareholder letter on March 31, 2026, detailing asset positions, cash, expenses, and strategic spin-outs.
Key points: an EXOZ stake valued at ~$30 million, Paulex seed funding of $19 million, year-end cash of ~$22.3 million, annual fixed operating expenses of ~$10 million, and net cash used of ~$5.7 million.
PatentVest (MDBH) released a Pulse report, “The Amylin Renaissance,” on March 31, 2026, detailing a rapid commercialization shift in amylin-based obesity therapies.
The report documents nearly 40 amylin receptor agonist programs, more than $19 billion in deal value committed over the past 18 months, clinical data showing up to 20%+ weight loss, an approaching FDA decision for a GLP-1/amylin combo, and growing oral small-molecule efforts. It emphasizes patent strategy as a decisive competitive factor.
PatentVest (NYSE:MDBH) added a new IP Legal Insights article on March 30, 2026, addressing patenting strategies for AI-assisted inventions. The piece, by Sarah Cork, Ph.D., Senior Patent Attorney, covers Section 101 eligibility, inventorship issues, claim drafting, and recent USPTO guidance shaping AI patent evaluation.
The article emphasizes demonstrating technological improvements, practical applications, and clear human contribution when seeking protection for AI-driven innovations.
PatentVest (MDBH) announced a strategic engagement with Life Seal Vascular on March 30, 2026, accepting equity as partial consideration for IP intelligence and legal services. The deal pairs PatentVest's proprietary IP platform with Life Seal Vascular's vascular device technology and signals a long-term commercial and strategic alignment.
The partnership aims to map competitive patent landscapes, identify patenting opportunities and risks, and inform R&D, licensing, and commercialization decisions for Life Seal Vascular.